Why Elevance Health Stock Is Back in Focus After Its Cancer Care Update

Elevance Health (ELV) is drawing fresh attention after expanding its connected cancer care model, which combines predictive analytics, clinical support, and oncology navigators to tighten care coordination and patient support.

The cancer care update comes after a period where Elevance Health's share price has been relatively resilient, with a 7 day share price return of 3.90% and a year to date share price return of 12.27%. The 1 year total shareholder return of 39.64% contrasts with a 3 year total shareholder return that is down 11.39%, suggesting recent momentum has picked up from a softer multi year experience.

If this kind of healthcare focused shift interests you, it can be useful to see what else is moving in the sector through the 43 healthcare AI stocks

Given Elevance Health's recent share price move and the current gap between the US$397.70 price and various fair value estimates, the key issue now is where in that range fair value genuinely sits.

Most Popular Elevance Health Narrative: 11.4% Undervalued

Based on the most followed narrative, Elevance Health's fair value of $449.10 sits above the last close of $397.70, which puts more weight on the cancer care update and broader Carelon strategy as potential value drivers.

Elevance's ongoing expansion of value-based care arrangements, particularly within behavioral health and oncology, and the scaling of risk-based contracts through its Carelon division, position the company to benefit from increased cost predictability, better care coordination, and reduced volatility in medical cost ratios, supporting future margin expansion.

The fair value call rests on a specific mix of slower headline revenue growth, improving margins and a lower future P/E than many healthcare peers. Curious which combination of earnings, cash flows and capital returns the narrative expects Elevance Health to deliver to bridge the gap between $397.70 and $449.10.

Result: Fair Value of $449.10 (UNDERVALUED)

However, Elevance Health still faces real pressure if Medicaid utilization stays elevated or if integration of recent Carelon acquisitions drags on margins longer than expected.

Next Steps

Given the mix of optimism and clear risks around Elevance Health, it makes sense to look at the numbers yourself and decide how they stack up. To see what potential positives other investors are watching, take a closer look at the 4 key rewards.

Looking For More Investment Ideas Beyond Elevance Health?

If you want to keep building your watchlist with fresh opportunities, use the Simply Wall St screener tools so you do not miss potential stand out stocks.

• Target resilient cash generative businesses by scanning a solid balance sheet and fundamentals stocks screener (48 results) that filters for companies with financial strength already measured for you.
• Spot potential value opportunities early with the 51 high quality undervalued stocks that highlights stocks priced below their assessed fundamentals before the crowd catches on.
• Lock in a steadier income stream by reviewing a 9 dividend fortresses that focuses on companies offering yields from 5% and above.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.